Medigene is developing Living Immunotherapies, with the goal of providing revolutionizing cancer treatments that offer a higher quality of life for patients.
We aim to enter strategic partnerships with interested parties to share the transformative potential of cancer immunotherapies with partners who truly believe in innovation.
Please contact our business development team if you are interested in discussing our clinical programs or want to develop new innovative immunotherapies based on our technologies to optimally tackle specific tumor types.
Developmental and Commercial Partnerships
In order to change the paradigm of cancer treatment, Medigene seeks partnerships with other leaders in the field to exploit the full potential of our immunotherapy technology platforms. Therefore, we are already collaborating with industry leaders:
bluebird bio, Inc., USA.
In September 2016, bluebird bio and Medigene established a strategic T cell receptor (TCR) alliance in cancer immunotherapy. The strategic research and development collaboration and licensing agreement encompasses T cell receptor (TCR)- immunotherapies against six targets (after an extension of the contract in May 2018). Under the terms of the agreement, Medigene will be responsible for the generation and delivery of the TCR-Ts using its TCR-isolation and characterization platform. Following collaborative preclinical development, bluebird bio will assume sole responsibility for the clinical development and commercialization of the TCR-T product candidates and will receive an exclusive license for the intellectual property covering the resulting TCR-Ts.
BioNTech IMFS GmbH , Germany
Medigene has signed an agreement with the contract manufacturer BioNTech IMFS GmbH (former EUFETS GmbH) in February 2016 for the production and delivery of viral vectors and cellular therapeutic products. BioNTech IMFS GmbH is an experienced contract manufacturing organization (CMO) that will take over further process development tasks and vector optimization processes, the establishment of different cell banks, and the batch production of viral vectors for Medigene's T cell receptor (TCR)- based cancer therapies. In addition, BioNTech IMFS serves as contract manufacturer for patient-individualized TCR-T therapeutics for use in clinical studies.
PHIO Pharmaceuticals Corp.
Medigene has a research collaboration with PHIO Pharmaceuticals Corp. (former RXi Pharmaceuticals Corporation) for exploring potential synergies of using PHIO's self-delivering RNAi technology (sd-rxRNA®) in combination with Medigene’s recombinant TCR-Ts to develop modified T cells with enhanced efficacy and/or safety. The preclinical research program will examine the applicability of PHIO’s sd-rxRNA technology to be integrated into Medigene’s process to produce receptor-modified T cells with the ultimate goal to further improve Medigene`s T cell therapies for the treatment of cancer patients.
Medigene has a research collaboration with Structured Immunity, a biotechnology company specializing in the optimization and validation of T cell receptor (TCR) proteins. Structured Immunity will provide structural immunology expertise in support of Medigene's TCR discovery activities. Under the terms of the agreement, Medigene will supply Structured Immunity with a lead TCR candidate for a high-profile solid tumor target. Structured Immunity will evaluate the TCR's specificity and recognition properties using their established structural immunology technologies
In order to support the development of our research projects, we have built an international scientific network through partnerships. Academic and clinical contacts and collaborations have been established with leading hospitals and institutions in Europe and in North America, such as:
Charité - Universitätsmedizin Berlin (Charité), Germany:
Max-Delbrück-Centre for Molecular Medicine in the Helmholtz-Gemeinschaft (MDC)
University Lausanne, Switzerland
University Hospital Oslo, Norway
Partnerships for non-core products
Veregen®: Distribution rights granted to various marketing partners
Medigene generates revenue from royalties, product sales, and milestone payments of Veregen®, a drug for the treatment of genital warts. Veregen® is based on a defined extract from green tea leaves and is currently available in the USA and Canada, in 20 European countries, and in Taiwan. Numerous marketing agreements for Veregen® are in place with international distribution partners:
In December 2017, Medigene sold the US rights of Veregen® to Fougera Pharmaceuticals, USA, and still holds all rights outside the US.
If you have any questions regarding marketing partnerships for our marketed products, please contact Michaela Fabry, Commercial Operations.
RhuDex®: Outlicensed to Dr. Falk Pharma GmbH
RhuDex® is an oral, disease modifying agent to treat autoimmune diseases. It is a CD80 antagonist that blocks undesired T-cell activation and production and therefore has both an immune-modulating and anti-inflammatory effect. The safety and tolerability of RhuDex® have been demonstrated in a number of Phase I clinical trials. Medigene has successfully completed a pilot Phase IIa trial in the indication rheumatoid arthritis. In 2013, Medigene outlined preparations for a further clinical development of RhuDex® in the indication of primary biliary cirrhosis (PBC).
In March 2014, Medigene signed a license agreement with the pharmaceutical company Dr. Falk Pharma GmbH, Freiburg, for the development and marketing rights to RhuDex® for hepatology and gastroenterology indications. Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex® in these therapeutic areas.
Falk Pharma has initially concentrated on development in primary biliary cirrhosis (PBC). Medigene retains the rights for RhuDex® in rheumatoid arthritis, psoriasis and other autoimmune diseases.